Patents by Inventor Beatriz Herrera

Beatriz Herrera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230248774
    Abstract: The invention is in the field of therapeutic treatment of tumours. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumour disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
    Type: Application
    Filed: April 17, 2023
    Publication date: August 10, 2023
    Applicant: Fresenius Medical Care Deutschland GmbH
    Inventors: Stefania BRUNO, Maria Beatriz HERRERA SANCHEZ, Valentina FONSATO, Giovanni CAMUSSI, Ciro TETTA
  • Publication number: 20230037275
    Abstract: There is disclosed a preparation of extracellular vesicles derived from human liver stem cells, preferably from a non-oval human progenitor cell line that expresses hepatic cell markers, which is capable of reducing the senescence of a population of senescent cells, as measured in a SA-?-galactosidase-based cellular senescence assay. Also disclosed are therapeutic applications of the preparation of extracellular vesicles derived from human liver stem cells according to the invention. Therapeutic applications include the reduction of cellular senescence, e.g. in an vitro or ex vivo method, as well as the therapeutic treatment of diseases and conditions known to be related to ageing and cellular senescence, such as for example atherosclerosis, diabetes mellitus type 2, asthenia, and others.
    Type: Application
    Filed: June 9, 2020
    Publication date: February 2, 2023
    Applicant: UNICYTE EV AG
    Inventors: Paul ROBBINS, Giovanni CAMUSSI, Maria Beatriz HERRERA SANCHEZ
  • Publication number: 20220226389
    Abstract: There is disclosed a preparation of extracellular vesicles derived from human liver stem cells, preferably from a non-oval human progenitor cell line that expresses hepatic cell markers, which is capable of reducing the senescence of a population of senescent cells, as measured in a SA-?-galactosidase-based cellular senescence assay. Also disclosed are therapeutic applications of the preparation of extracellular vesicles derived from human liver stem cells according to the invention. Therapeutic applications include the reduction of cellular senescence, e.g. in an vitro or ex vivo method, as well as the therapeutic treatment of diseases and conditions known to be related to ageing and cellular senescence, such as for example atherosclerosis, diabetes mellitus type 2, asthenia, and others.
    Type: Application
    Filed: June 9, 2020
    Publication date: July 21, 2022
    Applicant: Fresenius Medical Care Deutschland GmbH
    Inventors: Paul ROBBINS, Giovanni CAMUSSI, Maria Beatriz HERRERA SANCHEZ
  • Patent number: 11174497
    Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. Preferably, the alcohol is ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: November 16, 2021
    Assignees: VIB VZW, K.U. Leuven Research & Development
    Inventors: Kevin Verstrepen, Yudi Yang, Veerle Saels, Karin Voordeckers, Beatriz Herrera
  • Patent number: 10456425
    Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: October 29, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Patent number: 10357519
    Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 23, 2019
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Publication number: 20190060369
    Abstract: The invention is in the field of therapeutic treatment of tumours. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumour disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 28, 2019
    Applicant: Fresenius Medical Care Deutschland GmbH
    Inventors: Stefania BRUNO, Maria Beatriz HERRERA SANCHEZ, Valentina FONSATO, Giovanni CAMUSSI, Ciro TETTA
  • Publication number: 20180312878
    Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. The alcohol may be, e.g., ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.
    Type: Application
    Filed: September 2, 2016
    Publication date: November 1, 2018
    Applicants: VIB VZW, K.U. Leuven Research & Development
    Inventors: Kevin Verstrepen, Yudi Yang, Veerle Saels, Karin Voordeckers, Beatriz Herrera
  • Patent number: 10105395
    Abstract: The invention is in the field of therapeutic treatment of tumors. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumor effect when administered to a patient affected by a tumor disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: October 23, 2018
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Stefania Bruno, Maria Beatriz Herrera Sanchez, Valentina Fonsato, Giovanni Camussi, Ciro Tetta
  • Publication number: 20170348356
    Abstract: The invention is in the field of therapeutic treatment of tumors. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumor disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 7, 2017
    Applicant: Fresenius Medical Care Deutschland GmbH
    Inventors: STEFANIA BRUNO, Maria Beatriz Herrera Sanchez, Valentina Fonsato, Giovanni Camussi, Ciro Tetta
  • Patent number: 9717760
    Abstract: The invention is in the field of therapeutic treatment of tumors. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumor effect when administered to a patient affected by a tumor disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: August 1, 2017
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Stefania Bruno, Maria Beatriz Herrera Sanchez, Valentina Fonsato, Giovanni Camussi, Ciro Tetta
  • Publication number: 20170182100
    Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
    Type: Application
    Filed: January 23, 2017
    Publication date: June 29, 2017
    Inventors: Maria Beatriz HERRERA SANCHEZ, Valentina FONSATO, Ciro TETTA, Giovanni CAMUSSI
  • Patent number: 9334479
    Abstract: The invention relates to human liver pluripotent progenitor cell lines which express hepatic cell markers such as albumin and ?-fetoprotein and do not express some of the markers which are typical of oval stem cells. Also disclosed is a method of isolating the cell lines of the invention, methods for differentiating said cells into a plurality of different cell lineages, methods for conditional immortalization and metabolic selection of said cells, as well as the use of the cell lines of the invention for preparing a medicament with osteogenic differentiation activity or liver injury regeneration activity.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: May 10, 2016
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Benedetta Bussolati, Giovanni Camussi, Stefano Buttiglieri
  • Patent number: 9034335
    Abstract: The invention is in the field of therapeutic treatment of tumors. It has been found that the conditioned medium resulting from culturing an adult stem cell capable of differentiating into a plurality of differentiated cell types in a liquid cell culture medium and/or the adult stem cell from which the conditioned medium is obtainable, exert a remarkable anti-tumor effect. The adult stem cell derived conditioned medium preferred in this therapeutic application is a cell free conditioned medium derived from a human liver stem cell (HLSC).
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: May 19, 2015
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Publication number: 20120251489
    Abstract: The invention is in the field of therapeutic treatment of tumours. It has been found that the conditioned medium resulting from culturing an adult stem cell capable of differentiating into a plurality of differentiated cell types in a liquid cell culture medium and/or the adult stem cell from which the conditioned medium is obtainable, exert a remarkable anti-tumour effect. The adult stem cell derived conditioned medium preferred in this therapeutic application is a cell free conditioned medium derived from a human liver stem cell (HLSC).
    Type: Application
    Filed: December 7, 2010
    Publication date: October 4, 2012
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
  • Publication number: 20110129439
    Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.
    Type: Application
    Filed: June 11, 2009
    Publication date: June 2, 2011
    Inventors: Maria Beatriz Herrera Sanchez, Valentina Fonsato, Tetta Ciro, Camussi Giovanni
  • Publication number: 20100003752
    Abstract: The invention relates to human liver pluripotent progenitor cell lines which express hepatic cell markers such as albumin and ?-fetoprotein and do not express some of the markers which are typical of oval stem cells. Also disclosed is a method of isolating the cell lines of the invention, methods for differentiating said cells into a plurality of different cell lineages, methods for conditional immortalization and metabolic selection of said cells, as well as the use of the cell lines of the invention for preparing a medicament with osteogenic differentiation activity or liver injury regeneration activity.
    Type: Application
    Filed: May 24, 2006
    Publication date: January 7, 2010
    Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Maria Beatriz Herrera Sanchez, Benedetta Bussolati, Giovanni Camussi, Stefano Buttiglieri